On March 11, 2020 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, reported that it will release fourth quarter and annual financial results before market open on Monday, March 16, 2020 (Press release, AcelRx Pharmaceuticals, MAR 11, 2020, View Source [SID1234555432]). AcelRx management will host a live webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on March 16, 2020 to discuss the financial results and provide an update on the company’s business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast is accessible by visiting the Investors page of the company’s website at www.acelrx.com and clicking on the webcast link on the Investors home page. The webcast will be accompanied by a slide presentation. A webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company’s website at www.acelrx.com.

Investors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers.

On March 11, 2020 Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, reported the pricing of an underwritten public offering of 7,500,000 shares of its common stock, at a price to the public of $0.60 per share (Press release, Apricus Biosciences, MAR 11, 2020, View Source [SID1234555499]). In addition, the Company granted the underwriters a 45-day option to purchase up to 1,125,000 additional shares of its common stock to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by Seelos.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Benchmark Company is acting as sole book-running manager for the offering.

Seelos anticipates the aggregate net proceeds from the offering will be approximately $3.9 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Seelos, but excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates. This offering is expected to close on or about March 16, 2020, subject to the satisfaction of customary closing conditions.

The securities described above were offered by Seelos pursuant to a shelf registration statement on Form S-3 (File No. 333-221285) previously filed with the Securities and Exchange Commission (the "SEC") on November 2, 2017, amended on December 1, 2017 and declared effective by the SEC on December 7, 2017. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering has been filed with the SEC. Electronic copies of the preliminary prospectus and, when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC’s website at www.sec.gov or by contacting The Benchmark Company, LLC, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155, by calling (212) 312-6700 or by e-mail at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

On March 11, 2020 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, reported an expanded research collaboration with Cancer Research UK and the University of Manchester, UK, to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG) (Press release, Ideaya Biosciences, MAR 11, 2020, View Source [SID1234555417]). PARG is a cellular enzyme that hydrolyzes Poly (ADP-ribose) polymerase (PARP), a protein function required for DNA repair.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Since initiating the Cancer Research UK partnership in 2017, IDEAYA has developed a selective and cell potent PARG small molecule series, that demonstrates robust on-target in vivo pharmacodynamic modulation. In 2019, Dr. Stephen Taylor and Pilay et. al., published a paper in Cancer Cell, entitled "DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors", which provides a potentially differentiated and complementary treatment approach to PARP inhibitors.

The expanded research collaboration will evaluate IDEAYA’s PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models. Dr. Stephen Taylor, B.Sc., Ph.D., Leech Professor of Pharmacology, University of Manchester, the principal investigator at University of Manchester, will lead the in vitro investigations. Dr. Caroline Springer, Ph.D., Director, Drug Discovery Unit, Cancer Research UK Manchester Institute, the principal investigator at the Cancer Research UK Manchester Institute, will lead the in vivo studies.

"We are excited to expand our partnership with IDEAYA to evaluate key biological hypotheses based on DNA replication vulnerabilities to predict sensitivity of PARG inhibitors in ovarian cancer. A large percentage of ovarian cancer patients still do not respond to PARP inhibitors, and there is an important need to advance other synthetic lethality DDR-based targets," said Dr. Stephen Taylor, B.Sc., Ph.D. "This collaborative research builds on our existing relationship with IDEAYA, and could potentially inform effective patient selection strategies of PARG inhibitors," added Dr. Caroline Springer, Ph.D.

"Cancer Research UK has made important research contributions to the DNA Damage Repair and PARP-BRCA synthetic lethality field, and we are delighted to expand our partnership with this leading cancer research institute to advance our potential first-in-class PARG inhibitor program," said Yujiro S. Hata, Chief Executive Officer and President, IDEAYA Biosciences.

On March 11, 2020 Tiziana Life Sciences plc (NASDAQ: TLSA) (AIM: TILS) (the "Company" or "Tiziana"), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, reported the pricing of its underwritten follow-on public offering (the "Offering") of American Depositary Shares ("ADSs") on the NASDAQ Global Market (Press release, Tiziana Life Sciences, MAR 11, 2020, View Source [SID1234555433]). Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares of nominal value £0.03 each in the capital of the Company ("Ordinary Shares")) at a price to the public of $3.00 per ADS raising gross proceeds of approximately $10 million (before deducting underwriting discount, commissions and offering expenses). Each ADS offered represents five (5) Ordinary Shares. In addition, Tiziana has granted the underwriters a 45-day option to purchase up to an additional 500,000 ADSs on the same terms and conditions (the "Option"). All ADSs to be sold in the Offering will be offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering (including by way of the exercise of the Option) will be within existing shareholder authorities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as the sole book-running manager for the Offering.

The closing of the Offering is expected to occur on March 16, 2020, subject to customary closing conditions.

Tiziana intends to use the net proceeds received from this Offering (i) to advance the clinical development of Foralumab for Crohn’s Disease and progressive multiple sclerosis, (ii) to expedite clinical development of TZLS-501 for coronavirus COVID-19, and (iii) for working capital and other general corporate purposes.

Tiziana’s Ordinary Shares are admitted to trading on AIM, a market of the London Stock Exchange plc ("AIM"), under the symbol "TILS". The ADSs are listed for trading on the Nasdaq Global Market under the symbol "TLSA".

This Offering is being made pursuant to a registration statement on Form F-3, as amended (File No. 333-236013), previously filed with the U.S. Securities and Exchange Commission (the "SEC"), which became effective on February 6, 2020.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A preliminary prospectus supplement and accompanying base prospectus relating to this offering have been filed with the SEC and are available at the SEC’s website at View Source Before investing in Tiziana’s securities, you should read the preliminary prospectus supplement and the accompanying base prospectus and the documents incorporated by reference therein for information about Tiziana and this Offering. A final prospectus supplement related to the Offering will also be filed with the SEC.

Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at [email protected]. Electronic copies of the final prospectus supplement and accompanying prospectus will also be available on the SEC’s website at View Source

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue being Ordinary Shares and that following the issue of the Ordinary Shares to be issued in the Offering (excluding any to be issued pursuant to the Option), the total number of Ordinary Shares in issue will be 153,321,181. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

Application will be made to the London Stock Exchange for the Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur on or around 17 March 2020.

The figure of 153,321,181 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

Following admission of the Ordinary Shares to be issued in the Offering (excluding any to be issued pursuant to the Option), the fully diluted issued share capital of the Company will consist of 179,148,059 Ordinary Shares.

The person who arranged for the release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of Tiziana.

On March 11, 2020 LifeArc has reported that leading UK venture capital firm UK Innovation & Science Seed Fund (UKI2S) in investing into GyreOx Therapeutics (GyreOx) (Press release, LifeArc, MAR 11, 2020, View Source [SID1234555418]). The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The MACRO platform generates a range of highly modified macrocyclic peptide molecules, known as gyrocycles, which can penetrate cells and be targeted to tackle the protein-protein interactions (PPI) within. These intracellular processes are potentially implicated in many health conditions including cancer, inflammation and autoimmune diseases and are difficult to reach with currently available medicine classes. Automation of the MACRO platform will enhance the generation process further to allow a greater number of novel macrocycles to be generated more quickly and more cheaply.

Dr Bill Primrose, Founder and CEO of GyreOx said: "It’s a strong endorsement of our technology that we have been able to attract support from such quality investors. We have an ambitious plan to develop the platform and to deploy it on a number of internal programmes, including one targeting an epigenetic cancer target. It is our ambition to make GyreOx into a clinical stage company with a strong drug pipeline and a number of discovery alliances with major players in the pharmaceutical industry."

Common medicines classes include small molecules and biologics. While small molecules can enter cells to modulate intracellular process, they have difficulty in addressing complex targets, including PPIs. Biologics, such as humanised antibodies, are unable to enter the cell and are therefore only suitable for addressing drug targets on the cell surface. GyreOx’s Gyrocycle highly modified macrocyclic peptides combine the targeting ability of biologics with the cell-entry ability of small molecules; these molecules present an attractive, novel therapeutic modality as they can also be engineered to further improve their pharmacokinetic profile and ability to penetrate cells to reach previously "undruggable" targets.

Dr David Holbrook, Head of Seed Fund, LifeArc said: "The LifeArc Seed Fund is delighted to be supporting GyreOx on its work on the macrocycles platform and helping translate the science on the next step towards the patient. GyreOx is a great example of the type of company we are trying to support—great science, great scientists, strong start up management all addressing a significant unmet health need."

GyreOx Ltd. was founded in May 2019 as a result of the ground-breaking science carried out by Professor James Naismith (University of Oxford, previously at the University of St Andrews) and Professor Marcel Jaspars (University of Aberdeen). This seed investment has been led by UKI2S with LifeArc as the major investor and a contribution from Oxford University’s University Challenge Seed Fund. Part of the investment will also provide match funding for an Innovate UK grant to GyreOx.

Oliver Sexton, Investment Director UKI2S said: "GyreOx can design truly novel compounds with the ability to target intracellularly. This opens up a whole new drug space. UKI2S is excited to back such groundbreaking and medically important research."